MI Cancer Seek
The first FDA-approved test that sequences all of a tumour's genes and gene activity at once, used to match patients to several targeted drugs.
Overview
Caris Life Sciences' MI Cancer Seek was approved by the FDA in November 2024 as the first companion diagnostic combining whole-exome and whole-transcriptome sequencing, with claims covering several targeted and immune therapies across breast, colorectal, melanoma and lung cancers alongside tumour-profiling claims. The broad readout underpins Caris's real-world database, and the company's argument is that exome-plus-transcriptome captures fusions, expression and signatures that panels miss. Turnaround and tissue requirements are larger than for targeted panels.
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 2024 | Companion diagnostic claims across several solid tumours, with tumour-profiling claims |
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Notes
top- What a result means: one sample yields the full genomic picture; the companion claims matter for approved drugs, and the rest supports trial matching.
Latest papers
topQuery for this drug: (TITLE:"MI Cancer Seek" OR ABSTRACT:"MI Cancer Seek") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MI Cancer Seek, not a curated reading list.
Pages like this
not linked directly; found by shared links- ProductTempus xT CDx
Shares Next-generation sequencing (NGS), Companion diagnostics, Comprehensive genomic profiling, Colorectal cancer and the tag test.
- ProductTruSight Oncology Comprehensive
Shares Next-generation sequencing (NGS), Companion diagnostics, Comprehensive genomic profiling and the tag test.
- ProductOncomine Dx Target Test
Shares Next-generation sequencing (NGS), Companion diagnostics, Comprehensive genomic profiling, Non-small-cell lung cancer and the tag test.
- ProductGuardant Reveal
Shares Colorectal cancer, HR-positive / HER2-negative breast cancer, Non-small-cell lung cancer and the tag test.
- Producttherascreen companion diagnostic kits (KRAS, EGFR, PIK3CA, FGFR, BRAF)
Shares Companion diagnostics, Colorectal cancer, HR-positive / HER2-negative breast cancer, Non-small-cell lung cancer and the tag test.
- ProductResolution ctDx FIRST
Shares Companion diagnostics, Non-small-cell lung cancer and the tag test.
- ProductGuardant360 CDx
Shares Companion diagnostics, Comprehensive genomic profiling, HR-positive / HER2-negative breast cancer, Non-small-cell lung cancer and the tag test.
- ProductBreast Cancer Index
Shares RNA sequencing & expression profiling, HR-positive / HER2-negative breast cancer and the tag test.